Search results for " Chronic"

showing 10 items of 1458 documents

Will the COVID-19 pandemic affect HCV disease burden?

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Pneumonia ViralTime to treatmentAffect (psychology)Antiviral AgentsArticleTime-to-TreatmentBetacoronavirusPandemicHumansMedicineDisease EradicationPandemicsDisease burdenAntiviral AgentDisease EradicationbiologyHepatologyBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2GastroenterologyCOVID-19Hepatitis C Chronicbiology.organism_classificationVirologyCoronavirus InfectionsbusinessBetacoronavirusHuman
researchProduct

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

2020

2019-20 coronavirus outbreakPediatricsmedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)EpidemiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralPhiladelphia chromosomeSeverity of Illness IndexMyeloproliferative diseaseBetacoronavirusMyeloproliferative DisordersLeukemia Myelogenous Chronic BCR-ABL PositiveCorrespondenceNitrilesmedicineHumansPhiladelphia ChromosomeBetacoronavirus COVID-19 Coronavirus Infections Cross-Sectional Studies Disease Progression Humans Italy Leukemia Myelogenous Chronic BCR-ABL Positive Philadelphia Chromosome Pneumonia Viral Pyrazoles SARS-CoV-2 Severity of Illness Index Survival Analysis PandemicsPandemicsPhiladelphia negativebusiness.industrySARS-CoV-2Disease progressionCOVID-19Hematologymedicine.diseaseSurvival AnalysisCross-Sectional StudiesPyrimidinesItalyOncologyDisease ProgressionPyrazolesbusinessCoronavirus InfectionsCoronavirus InfectionsLeukemia
researchProduct

Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

2019

Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial…

3003AgonistDrugAlginatesCell Survivalmedicine.drug_classmedia_common.quotation_subjectSodium alginate polymerPharmaceutical ScienceChronic obstructive pulmonary disease (COPD)Inflammation02 engineering and technologyPharmacology030226 pharmacology & pharmacyCell LinePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinecAMPmedicineHumansAerodynamic diameterAdrenergic beta-2 Receptor AgonistsSalmeterol Xinafoatemedia_commonDrug CarriersCOPDInhalationChemistryTherapeutic effectAdhesiveness021001 nanoscience & nanotechnologymedicine.diseaseLipidsSALMETEROL XINAFOATEBronchodilator Agentsrespiratory tract diseasesSalmeterol Xinafoate (SX)MucusAerodynamic diametermedicine.symptom0210 nano-technologyInternational Journal of Pharmaceutics
researchProduct

Early ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis

2012

Monoclonal B Lymphocytosis (MBL) is defined as asymptomatic monoclonal B-cell expansion characterised by a CLL-phenotype, but with less than 5 x 10(9)/I circulating cells. Reactive oxygen species (ROS)-mediated cell damage plays a critical role in the initiation of carcinogenesis as well as in malignant transformation. The goal of this study was to perform an analysis of the oxidative stress statuses of patients affected by MBL and chronic lymphocytic leukaemia (CLL). We examined peripheral blood and urine specimens from 29 patients with MBL, 55 with CLL and 31 healthy subjects. There was a significant increase in the occurrence of the mutagenic base 8-oxo-2'-deoxiguanosine (8-oxo-dG) in th…

8-Oxo-dGMaleChronic lymphocytic leukaemiaCancer ResearchF-2-isoprostanesTime FactorsLymphocytosisDNA damageLymphocytosisBiologyDinoprostmedicine.disease_causeAntioxidantsLipid peroxidationchemistry.chemical_compoundMalondialdehydemedicineHumansCell damageChromatography High Pressure LiquidAgedchemistry.chemical_classificationB-LymphocytesReactive oxygen speciesGlutathione DisulfideDeoxyguanosineMonoclonal B LymphocytosisGlutathioneMiddle AgedMalondialdehydemedicine.diseaseGlutathioneLeukemia Lymphocytic Chronic B-CellOxidative StressOncologychemistryOxidative stress8-Hydroxy-2'-DeoxyguanosineImmunologyDNA damageFemalemedicine.symptomReactive Oxygen SpeciesBiomarkersOxidative stressDNA DamageCancer Letters
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Two cases of monomicrobial intraabdominal abscesses due to KPC - 3 Klebsiella pneumoniaeST258 clone

2011

Abstract Background Knowledge of the etiology of pyogenic liver and pancreatic abscesses is an important factor in determining the success of combined surgical and antibiotic treatment. Literature shows geographical variations in the prevalence and distribution of causative organisms, and the spread of Klebsiella pneumoniae carbapenemase-producing bacteria is an emerging cause of abdominal infections. Case presentation We herein describe two cases of intra-abdominal abscesses due to monomicrobial infection by Klebsiella pneumoniae Sequence Type 258 producing K. pneumoniae carbapenemase 3 (KPC-Kp). In case 1, a 50-year-old HIV-negative Italian woman with chronic pancreatitis showed infection…

<it>Klebsiellae pneumoniae</it>medicine.medical_specialtyAbdominal AbscessSettore MED/17 - Malattie Infettivecarbapenemasesmedicine.drug_classKlebsiella pneumoniaeAntibioticsMinocyclineCase ReportDrug resistanceTigecyclineTigecyclinebeta-LactamasesBacterial ProteinsDrug Resistance Multiple BacterialPancreatitis ChronicInternal medicinemedicineHumanslcsh:RC799-869Klebsiellae pneumoniaeSettore MED/12 - GastroenterologiabiologyColistinbusiness.industryAbdominal InfectionLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsSurgeryPancreatic NeoplasmsSettore MED/18 - Chirurgia GeneraleKlebsiella pneumoniaeColistinPancreatitislcsh:Diseases of the digestive system. Gastroenterologymonomicrobial abscess Klebsiellae pneumoniae carbapenemasesFemalebusinessmonomicrobial abscessmedicine.drugLiver abscessBMC Gastroenterology
researchProduct

Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Met…

2016

Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Methods and Findings Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. T…

ACE inhibitorsMyocardial InfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE inhibitor therapyBiochemistryRenin-Angiotensin SystemAnginachemistry.chemical_compoundEndocrinologyMathematical and Statistical Techniques0302 clinical medicineReninMedicine and Health SciencesSecondary Prevention030212 general & internal medicineMyocardial infarctionDiureticsStrokePharmaceuticsRDrugsEnzyme inhibitorsCardiovascular therapyGeneral Medicine3. Good healthHospitalizationStrokeNephrologyCardiovascular DiseasesPhysical SciencesCardiologyMedicineDrug therapyStatistics (Mathematics)Research Articlemedicine.drugAdultmedicine.medical_specialtyEndocrine DisordersCardiologyResearch and Analysis MethodsAngina PectorisDiabetes ComplicationsAngiotensin Receptor Antagonists03 medical and health sciencesDiabetes mellitusInternal medicineRenal DiseasesDiabetes MellitusmedicineHumansStatistical MethodsRenal Insufficiency ChronicPharmacologyHeart FailureCreatinineBiology and life sciencesbusiness.industryOdds ratiomedicine.diseasechemistryMetabolic DisordersHeart failuresistema cardiovascularACE inhibitorEnzymologyKidney Failure ChronicbusinessMathematicsMeta-AnalysisPLOS Medicine
researchProduct

Do ventilatory parameters influence outcome in patients with severe acute respiratory infection? Secondary analysis of an international, multicentre1…

2021

Purpose: To investigate the possible association between ventilatory settings on the first day of invasive mechanical ventilation (IMV) and mortality in patients admitted to the intensive care unit (ICU) with severe acute respiratory infection (SARI). Materials and methods: In this pre-planned sub-study of a prospective, multicentre observational study, 441 patients with SARI who received controlled IMV during the ICU stay were included in the analysis. Results: ICU and hospital mortality rates were 23.1 and 28.1%, respectively. In multivariable analysis, tidal volume and respiratory rate on the first day of IMV were not associated with an increased risk of death; however, higher driving pr…

ARDSSoins intensifs réanimationmedicine.medical_treatmentAirway pressuresPEEP positive end-expiratory pressureCritical Care and Intensive Care Medicinelaw.inventionHypoxemiaCohort StudiesPositive-Pressure RespirationMechanical ventilationSARI severe acute respiratory infectionlawHospital MortalityProspective StudiesIQR interquartile rangesProspective cohort studyRCT randomized controlled trialTidal volumeSOFA Sequential Organ Failure AssessmentSAPS Simplified Acute Physiology ScoreIntensive care unitVCV volume-controlled ventilationHIV human immunodeficiency virusIntensive Care UnitsIC GLOSSARI Intensive Care Global Study on Severe Acute Respiratory Infectionmedicine.symptomCohort studyLOS length of staymedicine.medical_specialtyVt tidal volumeCOPD Chronic obstructive pulmonary diseaseNYHA New York Heart Association.PCV pressure-controlled ventilationArticleInternal medicineICU Intensive Care UnitSIMV Synchronized intermittent mandatory ventilationmedicineTidal VolumeHumansDP driving pressurePEEPARDS acute respiratory distress syndromeMechanical ventilationbusiness.industryOdds ratioPneumoniaPlateau pressuremedicine.diseaseRespiration ArtificialVILI ventilator induced lung injuryCI confidence intervalOR odds ratioIMV invasive mechanical ventilationCPAP continuous positive airway pressureARDSbusinessSD standard deviationECMO extracorporeal membrane oxygenationPBW predicted body weightPplat plateau pressure
researchProduct

Pattern of macrovascular invasion in hepatocellular carcinoma

2021

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed …

Ablation TechniquesMaleRegistrieCirrhosisClinical BiochemistryMesenteric Veinloco-regional treatment030204 cardiovascular system & hematologyBiochemistryGastroenterologysurgeryAntineoplastic AgentLiver disease0302 clinical medicineNon-alcoholic Fatty Liver Diseasecirrhosis; hepatocellular carcinoma; loco-regional treatment; portal vein thrombosis; surgery; transplantationAscitesAblation Techniqueportal vein thrombosisRegistries030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaPortal VeinLiver DiseasesLiver NeoplasmsAsciteshepatocellular carcinomaGeneral MedicineMiddle AgedSorafenibPrognosisHepatitis BAlcoholicHepatitis CTumor BurdenSurvival RateItalyLiver NeoplasmHepatocellular carcinomaAsciteFemalemedicine.symptomLiver cancerHumanmedicine.medical_specialtyCarcinoma HepatocellularPrognosiAntineoplastic AgentsEnd Stage Liver Disease03 medical and health sciencesMesenteric VeinsHepatitis B ChronicInternal medicinemedicineHumansHepatectomyNeoplasm Invasivenessportal vein thrombosiLiver Diseases AlcoholicAgedNeoplasm Invasivene...Performance statusbusiness.industrycirrhosisCarcinomaSettore MED/09 - MEDICINA INTERNAPatient AcuityHepatocellularHepatitis C Chronicmedicine.diseaseLiver TransplantationTransplantationLiver functionbusinesscirrhositransplantationEuropean Journal of Clinical Investigation
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct